# Addex Therapeutics Ltd.: Form 20-F for the period ended Dec 31, 2019

- Company: [Addex Therapeutics Ltd.](/companies/adxn.md) (CIK 1574232)
- Form: 20-F
- Filed: 2020-04-27
- Accepted by EDGAR: Apr 24, 2020, 21:19 ET
- Period: 2019-12-31
- Accession: 0001047469-20-002580
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1574232/000104746920002580/a2241359z20-f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1574232/000104746920002580/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2019-01-01 to 2019-12-31 | CHF 2.8m | ifrs-full:RevenueFromContractsWithCustomers |
| Operating income | 12 months, 2019-01-01 to 2019-12-31 | −CHF 14.6m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months, 2019-01-01 to 2019-12-31 | −CHF 14.8m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months, 2019-01-01 to 2019-12-31 | −CHF 9.5m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2019-01-01 to 2019-12-31 | CHF 28.5k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2019-12-31 | CHF 31.5m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2019-12-31 | CHF 32.4m | ifrs-full:CurrentAssets |
| Total assets | at 2019-12-31 | CHF 33.0m | ifrs-full:Assets |
| Current liabilities | at 2019-12-31 | CHF 5.7m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | at 2019-12-31 | CHF 25.5m | ifrs-full:Equity |
| Shares outstanding | at 2019-12-31 | 32,848,635 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1574232/000104746920002580/a2241359z20-f.htm

Filed Apr 27, 2020.
Source: SEC EDGAR, the filing index for accession 0001047469-20-002580. Last ingested by Listed: Oct 29, 2026, 06:06 ET. No prices; not investment advice.